SVF
Level A· Stronger Clinical EvidenceSystematic Review

Safety and Efficacy of Adipose-Derived Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: A Systematic Review.

Giugni FR., Giugni MOV., Pinesi HT., Habrum FC., Laranjeira LN., Sady ERR.

Systematic Review on Cardiovascular Disease, published in Arq Bras Cardiol (2024) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Arq Bras Cardiol (2024)
Country
Brazil
Reported sample size
—
PMID
39292063
DOI
10.36660/abc.20230830

Abstract (original English)

Cell therapy using adipose-derived mesenchymal stem cells (ADSCs) shows great potential as a treatment for cardiovascular diseases. We conducted a systematic review to describe the safety and efficacy of ADSCs in ischemic heart disease. We searched PubMed/MEDLINE, EMBASE, Web of Science, CENTRAL, and LILACS (from inception to March 2024) for clinical studies involving ADSCs in patients with ischemic heart disease. We excluded studies involving patients with other types of heart disease, studies using mesenchymal stem cells derived from other tissues, as well as ongoing studies. Two independent reviewers screened the retrieved citations, extracted relevant data, and assessed the risk of bias in the included trials, using the Cochrane Collaboration criteria modified by McMaster University and Methodological Index for Non-Randomized Studies (MINORS). We used a narrative synthesis to present the results. Ten studies (comprising 29 publications) met our inclusion criteria, including 8 randomized controlled trials and 2 uncontrolled trials. No severe adverse events associated with ADSC therapy were reported. While most efficacy endpoints did not reach statistical significance, there were reports of improved ischemic area, functional capacity, symptoms, and contractility in patients treated with ADSCs. The findings from our review suggest that ADSC therapy is generally safe for patien

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansMesenchymal Stem Cell TransplantationMyocardial IschemiaAdipose TissueTreatment OutcomeMesenchymal Stem Cells
Systemic / IVCardiovascular Disease
View on PubMedDOI

Related research